InsiderTrades.com logo
J. Anthony Ware net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

J. Ware Biography and Net Worth

Director of First Tracks Biotherapeutics

Dr. Ware served as the Senior Vice President of Product Development of Lilly Bio-Medicines at Eli Lilly and Company, where he was responsible for the clinical development and regulatory approval of new medicines in multiple therapeutic areas. His sixteen year tenure at Eli Lilly has included the clinical development, regulatory approval and launch of numerous novel therapeutics, including Taltz®, Olumiant®, Cymbalta®, Cialis®, Effient® and Trulicity®. Prior to Eli Lilly, Dr. Ware served as Professor of Medicine and Molecular Pharmacology at Albert Einstein College of Medicine in New York, where he was also Chief of Cardiology at Montefiore Medical Center. Before then, Dr. Ware was on the faculty of Harvard Medical School and also served as a senior physician and Director of the Coronary Care Unit at Beth Israel Hospital. Dr. Ware received a Bachelor of Science degree from Washburn University, a Medical Degree from the University of Kansas, has served in internships at the University of Texas at Houston and Baylor College of Medicine, and is board certified both in internal medicine and cardiovascular disease.

How do I contact J. Anthony Ware?

The corporate mailing address for Dr. Ware and other First Tracks Biotherapeutics executives is 10770 WATERIDGE CIRCLE SUITE 210, SAN DIEGO, CA 92121, US. First Tracks Biotherapeutics can also be reached via phone at 858-362-6295 and via email at [email protected]. Learn More on J. Anthony Ware's contact information.

Has J. Anthony Ware been buying or selling shares of First Tracks Biotherapeutics?

J. Anthony Ware has not been actively trading shares of First Tracks Biotherapeutics in the last ninety days. Learn More on J. Anthony Ware's trading history.

Are insiders buying or selling shares of First Tracks Biotherapeutics?

During the last twelve months, insiders at the sold shares 1 times. They sold a total of 39,265 shares worth more than $1,758,286.70. The most recent insider tranaction occured on September, 2nd when Director J. Anthony Ware sold 39,265 shares worth more than $1,758,286.70. Learn More about insider trades at First Tracks Biotherapeutics.

Information on this page was last updated on 9/2/2026.

J. Anthony Ware Insider Trading History at First Tracks Biotherapeutics

See Full Table

J. Anthony Ware Buying and Selling Activity at First Tracks Biotherapeutics

This chart shows J. Anthony Ware's buying and selling at First Tracks Biotherapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

First Tracks Biotherapeutics Company Overview

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.
Read More

Today's Range

Now: $39.57
Low: $39.31
High: $42.79

50 Day Range

MA: $39.14
Low: $18.59
High: $47.92

2 Week Range

Now: $39.57
Low: $14.72
High: $49.91

Volume

478,531 shs

Average Volume

630,977 shs

Market Capitalization

$1.41 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A